Valuation: GlaxoSmithKline plc

Market Cap 8.04TCr 11TCr 9.39TCr 8.76TCr 15TCr 10,23300Cr 15TCr 1,03900Cr 41TCr 5,06400Cr 40TCr 39TCr 17,50600Cr P/E 2026 *
12.8x
P/E 2027 * 11.7x
Enterprise Value 10TCr 14TCr 12TCr 11TCr 19TCr 12,96600Cr 20TCr 1,31700Cr 51TCr 6,41600Cr 51TCr 50TCr 22,18100Cr EV / Sales 2026 *
3x
EV / Sales 2027 * 2.62x
Free-Float
93.18%
Yield 2026 *
3.47%
Yield 2027 * 3.64%
Manager TitleAgeSince
Chief Executive Officer - 01/01/2026
Director of Finance/CFO 64 01/05/2023
Chief Tech/Sci/R&D Officer - 01/12/2021
Director TitleAgeSince
Director/Board Member - 06/05/2026
Director/Board Member 64 01/01/2018
Chairman 68 01/09/2019
Change 5-day change 1-year change 3-year change Capi.($)
-0.87%+4.04%+58.60%+163.92% 1,08900Cr
-0.45%+3.87%+57.95%+52.18% 64TCr
+0.04%+3.95%+37.69%+74.54% 47TCr
-1.69%+8.81%+39.38%+34.26% 36TCr
-0.51%+3.51%+36.97%+43.76% 30TCr
+1.50%+3.40%+17.71%+18.77% 27TCr
+0.79%+5.81%-2.55%-36.02% 23TCr
-1.39%+5.90%+27.70%+64.00% 21TCr
-1.18%+1.83%+16.20%+72.69% 17TCr
Average -0.42%+4.77%+32.18%+54.23% 41.46TCr
Weighted average by Cap. -0.51%+4.90%+41.99%+79.01%

Financials

2026 *2027 *
Net sales 3.4TCr 4.51TCr 3.97TCr 3.7TCr 6.36TCr 4,32200Cr 6.52TCr 44TCr 17TCr 2,13900Cr 17TCr 17TCr 7,39400Cr 3.56TCr 4.74TCr 4.16TCr 3.88TCr 6.67TCr 4,53600Cr 6.84TCr 46TCr 18TCr 2,24400Cr 18TCr 17TCr 7,75900Cr
Net income 639.09Cr 849.02Cr 746.04Cr 696.37Cr 1.2TCr 81TCr 1.23TCr 8.26TCr 3.23TCr 40TCr 3.19TCr 3.12TCr 1,39100Cr 695.47Cr 923.94Cr 811.86Cr 757.81Cr 1.3TCr 88TCr 1.33TCr 8.99TCr 3.51TCr 44TCr 3.47TCr 3.39TCr 1,51400Cr
Net Debt 2.15TCr 2.85TCr 2.51TCr 2.34TCr 4.02TCr 2,73300Cr 4.12TCr 28TCr 11TCr 1,35200Cr 11TCr 10TCr 4,67500Cr 1.29TCr 1.71TCr 1.51TCr 1.41TCr 2.42TCr 1,64200Cr 2.48TCr 17TCr 6.52TCr 81TCr 6.44TCr 6.3TCr 2,80900Cr
Logo GlaxoSmithKline plc
GSK plc is the world's No. 2 pharmaceutical group. Net sales break down by family of products as follows: - pharmaceutical products (41.3%): intended mainly for HIV infection (57% of net sales), immune system disorders and respiratory diseases (28.3%), and cancer (14.7%); - OTC and parapharmaceutical medicine (30.7%); - vaccines (28%). Net sales are distributed geographically as follows: the United Kingdom (2.1%), Europe (21%), the United States (51.6%), and other (25.3%).
Employees
-
Trader
Investor
Global
Quality
ESG MSCI
-